within Pharmacolibrary.Drugs.ATC.L;

model L01DB07
  extends Pharmacokinetic.Models.PK_3C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0003,
    adminDuration  = 600,
    adminMass      = 12 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0214,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01DB07</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>3</td></tr></table><p>Mitoxantrone is an antineoplastic agent in the class of anthracenediones, used for the treatment of certain types of cancer (including breast cancer, non-Hodgkin's lymphoma, and acute myeloid leukemia), and also for secondary progressive multiple sclerosis. It is an approved drug, although its use is limited by potential cardiac toxicity.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult cancer patients (various tumor types), predominantly female, with intravenous administration.</p><h4>References</h4><ol><li><p>Batra, VK, et al., &amp; Yacobi, A (1986). Pharmacokinetics of mitoxantrone in man and laboratory animals. <i>Drug metabolism reviews</i> 17(3-4) 311–329. DOI:<a href=&quot;https://doi.org/10.3109/03602538608998294&quot;>10.3109/03602538608998294</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3552542/&quot;>https://pubmed.ncbi.nlm.nih.gov/3552542</a></p></li><li><p>Kochevar, DT, et al., &amp; Polzer, JP (1995). Pharmacokinetics and haematological effects of a single intravenous dose of mitoxantrone in cats. <i>Journal of veterinary pharmacology and therapeutics</i> 18(6) 471–475. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2885.1995.tb00629.x&quot;>10.1111/j.1365-2885.1995.tb00629.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8789703/&quot;>https://pubmed.ncbi.nlm.nih.gov/8789703</a></p></li><li><p>Ehninger, G, et al., &amp; Blanz, J (1990). Pharmacokinetics and metabolism of mitoxantrone. A review. <i>Clinical pharmacokinetics</i> 18(5) 365–380. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199018050-00003&quot;>10.2165/00003088-199018050-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2185907/&quot;>https://pubmed.ncbi.nlm.nih.gov/2185907</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01DB07;
